公开(公告)号：US20220054635A1

公开(公告)日：2022-02-24

申请号：US17519790

申请日：2021-11-05

申请人： Hoffmann-La Roche Inc.

发明人： Marina BACAC ,  Stefan EVERS ,  Christian KLEIN ,  Pavel PISA ,  Eva ROSSMANN ,  Jose SARO ,  Pablo UMANA

IPC分类号： A61K39/395 ,  C07K16/30 ,  C07K16/28

摘要： The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of adverse effects in response to the administration of a therapeutic agent, particularly a T-cell activating therapeutic agent.

公开(公告)号：US20200376119A1

公开(公告)日：2020-12-03

申请号：US16787931

申请日：2020-02-11

申请人： Hoffmann-La Roche Inc.

发明人： Marina BACAC ,  Sara COLOMBETTI ,  Christian KLEIN ,  Johannes SAM ,  Jose SARO ,  Pablo UMANA

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/30

摘要： The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.

公开(公告)号：US20230052521A1

公开(公告)日：2023-02-16

申请号：US17748707

申请日：2022-05-19

申请人： Hoffmann-La Roche Inc.

发明人： Marina BACAC ,  Stefan EVERS ,  Christian KLEIN ,  Pavel PISA ,  Eva ROSSMANN ,  Jose SARO ,  Pablo UMANA

IPC分类号： A61K39/395 ,  C07K16/30 ,  C07K16/28

摘要： The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of adverse effects in response to the administration of a therapeutic agent, particularly a T-cell activating therapeutic agent.

公开(公告)号：US20210252144A1

公开(公告)日：2021-08-19

申请号：US17240821

申请日：2021-04-26

申请人： Hoffmann-La Roche Inc.

发明人： Marina BACAC ,  Stefan EVERS ,  Christian KLEIN ,  Pavel PISA ,  Eva ROSSMANN ,  Jose SARO ,  Pablo UMANA

IPC分类号： A61K39/395 ,  C07K16/30 ,  C07K16/28

摘要： The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of adverse effects in response to the administration of a therapeutic agent, particularly a T-cell activating therapeutic agent.